I49.8 Insurance Policy Changes

ICD-10 I49.8 is officially defined as "Other specified cardiac arrhythmias." code I49.8 is referenced in 22 tracked payer policy changes from Medicare/CMS - Transmittals, UnitedHealthcare, and 5 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code I49.8 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medicare/CMS - Transmittals · Effective Apr 1, 2027Medium impact
R14022OTN: International Classification of Diseases, 10th Revision (ICD-10) and Other Coding Revisions to National Coverage Determinations (NCDs)- April 2027.
CMS Transmittal 14022, dated October 23, 2026, is a quarterly maintenance update of ICD-10 coding and other coding updates for National Coverage Determinations, and it states that no policy is being changed as a result of these updates. The transmittal's stated effective date is April 1, 2027, with an implementation date of April 5, 2027, while the code changes in its table are dated September 30, 2026 (end dates) and October 1, 2026 (additions). The table also adds CPT 81459 for PGDX elio tissue complete CDx effective FDA approval July 30, 2026, until a specific PLA code is established, and adds HCPCS J9066 to the chemotherapy drugs associated with NCD 110.18 effective October 1, 2026.
UnitedHealthcare · Effective Oct 1, 2026High impact
Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (UMR)
UnitedHealthcare's UMR medical policy update bulletin for October 2026 says the annual ICD-10 and quarterly CPT/HCPCS code changes took effect October 1, 2026 across its medical and drug policies. The billing team needs to add the new CPT, HCPCS and ICD-10 codes to charge entry, stop using the codes that were removed, and update the revised descriptions. The bulletin lists the code changes but does not state any coverage decisions beyond the policies it updates, so the practice should check each updated policy before billing the new codes.
UnitedHealthcare · Effective Oct 1, 2026High impact
Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (Surest)
UnitedHealthcare's Surest medical policy update bulletin for October 2026 says the annual ICD-10 and quarterly CPT/HCPCS code changes took effect October 1, 2026 across its medical and drug policies. The billing team needs to add the new CPT, HCPCS and ICD-10 codes to charge entry, stop using the codes that were removed, and update the revised descriptions. The bulletin lists the code changes but does not state any coverage decisions beyond the policies it updates, so the practice should check each updated policy before billing the new codes.
UnitedHealthcare · Effective Oct 1, 2026High impact
Preventive Care Services
UnitedHealthcare's individual exchange (ACA marketplace) preventive care policy was updated effective October 1, 2026, which is already in effect. The update refreshed the pregnancy ICD-10 diagnosis codes, added several sudden cardiac arrest and death diagnosis codes while removing two, added breast MRI codes 76014 through 76019 and A9573 for completing breast cancer screening, and clarified that certain colonoscopies may need a site of service review.
UnitedHealthcare · Effective Oct 1, 2026High impact
Preventive Care Services
UnitedHealthcare's commercial preventive care policy was updated effective October 1, 2026, which is already in effect. The update refreshed the pregnancy ICD-10 diagnosis codes, added several sudden cardiac arrest and death diagnosis codes while removing two, added breast MRI codes 76014 through 76019 and A9573 for completing breast cancer screening, and clarified that certain colonoscopies may need a site of service review.
Blue Cross & Blue Shield of Mississippi · Effective Oct 1, 2026High impact
Autonomic Nervous System Testing
The Code Reference section was updated on 10/01/2026 to add ICD-10 diagnosis codes I49.81 (Brugada syndrome), I49.82 (ventricular bigeminy), and I49.89 (other specified cardiac arrhythmias not elsewhere classified). The code I49.8 (other specified cardiac arrhythmias) is shown as deleted 09/30/2026, and ICD-9 diagnosis codes were removed. The policy states that ANS testing may be considered medically necessary to evaluate symptoms of vasomotor instability after more common causes have been excluded by other testing, for the listed indications, and is investigational for all other indications.
Blue Cross & Blue Shield of Mississippi · Effective Oct 1, 2026High impact
Implantable Cardioverter Defibrillator
Transvenous implantable cardioverter defibrillator use for primary prevention may be considered medically necessary in adults with ischemic cardiomyopathy, nonischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, cardiac ion channelopathies or cardiac sarcoid when the listed criteria are met, and for secondary prevention after a life-threatening ventricular arrhythmic event. A subcutaneous ICD may be considered medically necessary when the listed criteria are met, including a contraindication to a transvenous ICD, while an extravascular ICD is considered investigational. Effective 10/01/2026, ICD-10 diagnosis codes I42.00, I42.01, I42.09, I42.81, I42.89, I47.22, I49.81, I49.82 and I49.89 were added, and I42.0, I42.8 and I49.8 were deleted as of 09/30/2026.
Blue Cross Blue Shield of North Dakota · Identified Oct 24, 2026High impact
Medical Policy Updates for Non-Migrated Members
Blue Cross Blue Shield of North Dakota's October 22, 2026 notice for non-migrated commercial and Medicaid Expansion members lists medical policies reviewed by its Internal Medical Policy Committee on Oct. 13, 2026. The revised policies include reformatted criteria and policies with coding changes, such as procedure codes and diagnosis codes added to or removed from policies, including physical therapy covered-diagnosis lists and Category III T codes. The notice also lists tabled policies (Tumor Markers, where further research is needed) and states that benefit determinations are made based on the medical policy in effect at the time of service.
UnitedHealthcare · Effective Nov 1, 2026Medium impact
Ambulatory Electrocardiographic (AECG) Monitoring
UnitedHealthcare's Medicare Advantage bulletin for November 2026 updated its Ambulatory Electrocardiographic (AECG) Monitoring policy, adding diagnosis codes I42.00, I42.01, I42.09, I42.81, I42.89, I47.22, I49.81, I49.82, and I49.89 to the applicable-codes list for CPT 93224–93229, 93241–93248, 93268, 93270–93272, and 0937T–0940T. The bulletin also notes that I42.0 and I49.8 were deleted Sep. 30, 2026, and the coverage document list was refreshed. Billing teams should update diagnosis coding for AECG monitoring claims to use the newly listed codes.
UnitedHealthcare · Effective Oct 1, 2026Medium impact
Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (Exchange)
Effective October 1, 2026, UnitedHealthcare updated several Individual Exchange medical policies to match the annual ICD-10 and quarterly CPT/HCPCS code changes. The bulletin adds many new codes across areas such as cardiology, pregnancy, hematology, genetic testing and pain or rehabilitation, and it removes a smaller set of older codes.
UnitedHealthcare · Effective Oct 1, 2026Medium impact
Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (Commercial)
UnitedHealthcare's Commercial medical and drug policies were updated effective October 1, 2026 to match the annual ICD-10 and quarterly CPT/HCPCS code changes. Codes were added, revised or removed across topics including genetic testing, molecular oncology, cell therapy, pregnancy preventive care, sudden cardiac arrest risk and Category III codes, so the billing team needs to update its code lists and charge entry tables to match.
Independence Blue Cross · Effective Oct 1, 2026Medium impact
MA11.060i, Catheter Ablation of Cardiac Arrhythmias
Independence Blue Cross updated MA11.060i effective 10/01/2026 to reflect ICD-10 code changes for catheter ablation of cardiac arrhythmias. The terminated code I49.8 (Other specified cardiac arrhythmias) has been replaced with three new codes: I49.81 (Brugada syndrome), I49.82 (Ventricular bigeminy), and I49.89 (Other specified cardiac arrhythmias not elsewhere classified). Billing teams must update diagnosis code mappings in their systems to ensure accurate claims submission.
Independence Blue Cross · Effective Oct 1, 2026Medium impact
MA11.011i, Ventricular Assist Devices (VADs)
Independence Blue Cross updated VAD policy MA11.011i with ICD-10 code changes effective 10/01/2026, replacing nine outdated diagnosis codes with nine more specific codes reflecting current cardiac condition classifications. Additionally, the policy reaffirms requirement that VAD patients must be managed by an explicitly identified multidisciplinary team at approved facilities.
UnitedHealthcare · Effective Oct 1, 2026Medium impact
Preventive Care Services
UnitedHealthcare and Surest updated the Preventive Care Services medical policy, effective October 1, 2026. The changes add or remove diagnosis codes for pregnancy, sudden cardiac arrest and family history, add breast MRI codes used to complete a breast cancer screening, and clarify that some colonoscopies may need a site of service review.
Excellus BlueCross BlueShield · Effective Jul 16, 2026Medium impact
Cardiac Event Monitors 2.01.03
External intermittent cardiac event monitors are medically appropriate for symptoms possibly related to rhythm disturbances (such as palpitations, or serious or significant syncope and near syncope), after an ablation, and after starting or stopping anti-arrhythmic drug therapy, when the specific criteria are met. Implantable loop recorders may be considered medically appropriate for specified indications, such as infrequent recurrent syncope, near syncope, or palpitations, paroxysmal atrial fibrillation, cryptogenic stroke, and post cardiac ablation, when the criteria are met, and home-based mobile cardiac outpatient telemetry is considered not medically necessary. External monitoring to measure heart rate variability or to detect ST segment changes, and intracardiac ischemia event monitors, are investigational.
Excellus BlueCross BlueShield · Effective May 21, 2026Medium impact
Genetic Testing for Cardiac Ion Channelopathies 2.02.38
Excellus BlueCross BlueShield medical policy 2.02.38, Genetic Testing for Cardiac Ion Channelopathies, has a current effective date of May 21, 2026, and its annual review on that date left the policy intent unchanged. Genetic testing for congenital long QT syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT) and Brugada syndrome is medically appropriate when signs or symptoms are present but a definitive diagnosis cannot be made without it, or for at-risk individuals who have a qualifying first-, second- or third-degree relative, in each case only when the test results will influence treatment decisions. Genetic testing to determine future risk of short QT syndrome (SQTS) is medically appropriate for asymptomatic individuals who have a first-, second- or third-degree relative with a known SQTS variant.
Aetna · Identified Oct 2, 2026Medium impact
Cardiac Catheter Ablation (CPB 0165, reviewed 2026-08-25)
Aetna considers cardiac catheter ablation with electrophysiological studies medically necessary for listed atrial fibrillation, atrioventricular nodal reentrant tachycardia, atrial tachycardia and flutter, accessory pathway, and ventricular arrhythmia indications, each with its own clinical conditions such as symptoms, drug failure or intolerance, or a high-risk accessory pathway. Pulsed field ablation is considered an equally acceptable alternative to standard radiofrequency ablation for medically necessary indications. Ablation for all other indications is considered experimental, investigational, or unproven, and so are alcohol ablation of the vein of Marshall, the AtriCure Isolator Synergy EnCompass Clamp, cardio-neuro-ablation, intra-myocardial infusion-needle catheter ablation for ventricular tachycardia, non-invasive cardiac radio-ablation, and sinus node-sparing hybrid ablation.
Aetna · Identified Aug 18, 2026Medium impact
Tilt Table Testing (CPB 0299, reviewed 2026-05-15)
Aetna's Clinical Policy Bulletin 0299 considers tilt table testing, alone or with isoproterenol or sublingual nitroglycerin, medically necessary as part of the diagnostic workup for suspected postural orthostatic tachycardia syndrome (POTS) and for evaluating unexplained syncope or near syncope when criteria are met. For syncope, the member must have recurrent syncope or presyncope, or one episode considered high risk of physical injury, and the initial evaluation must be inconclusive or equivocal. Aetna considers tilt table testing experimental, investigational, or unproven for other indications, including joint hypermobility syndrome, differential diagnosis of parkinsonian syndromes, dizziness alone when orthostatic hypotension is not suspected, vertigo, post-concussion syndrome, and chronic fatigue syndrome.
Aetna · Identified Aug 17, 2026Medium impact
Apnea Monitors for Infants (CPB 0003, reviewed 2026-03-05)
Aetna considers apnea monitors medically necessary durable medical equipment for infants less than 12 months of age with documented apnea or known risk factors for life-threatening apnea. Covered indications include pertussis with positive cultures, documented apnea with bradycardia below 80 beats per minute, marked hypotonia, oxygen desaturation below 90 percent, cyanosis or pallor, gastro-esophageal reflux causing apnea, bradycardia or desaturation, and prolonged apnea of greater than 20 seconds. Infant apnea monitors for all other indications are considered experimental, investigational, or unproven.
Aetna · Identified Aug 17, 2026Medium impact
Leadless Cardiac Pacemaker (CPB 0893, reviewed 2025-12-22)
Aetna considers FDA-approved leadless cardiac pacemakers, such as the Micra and Aveir systems, medically necessary when the member has symptomatic paroxysmal or permanent high-grade atrioventricular block, symptomatic bradycardia-tachycardia syndrome, or sinus node dysfunction (sinus bradycardia or sinus pauses), and also has a significant contraindication that precludes placement of conventional single chamber ventricular pacemaker leads. The listed contraindications are a history of an endovascular or cardiovascular implantable electronic device (CIED) infection or high risk for infection, limited access for trans-venous pacing, and the presence of a bio-prosthetic tricuspid valve. Aetna considers leadless pacemakers experimental, investigational, or unproven for all other indications, and considers a leadless pacemaker combined with cardiac resynchronization therapy, or with a subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death, experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Quantitative Sensory Testing Methods (CPB 0357, reviewed 2026-05-22)
Quantitative sensory testing (QST), current perception threshold (CPT) testing, voltage-actuated sensory nerve conduction threshold (VsNCT) testing, and quantitative thermal testing for early diagnosis of leprosy are considered experimental, investigational, or unproven for the uses listed in this policy, because their effectiveness or clinical value has not been established. Listed uses include evaluating fibromyalgia pain, chronic itch, chronic pelvic pain, and shoulder pain, and diagnosing restless legs syndrome and small fiber neuropathy in postural orthostatic tachycardia syndrome. CPT codes 0106T through 0110T and HCPCS code G0255 are not covered for the listed indications.
Aetna · Identified Aug 15, 2026Medium impact
Cardiac Catheter Ablation (CPB 0165)
Aetna considers catheter ablation with electrophysiological studies medically necessary for atrial fibrillation, AVNRT, atrial tachycardia and atrial flutter, accessory pathways, and ventricular arrhythmias when the listed criteria are met, such as symptomatic AF when antiarrhythmic drugs have been ineffective, contraindicated, not tolerated or not preferred. Aetna considers catheter ablation for all other indications experimental, investigational or unproven. The policy also lists alcohol ablation of the vein of Marshall, the AtriCure Isolator Synergy EnCompass Clamp, cardio-neuro-ablation for carotid sinus hypersensitivity syncope, intra-myocardial infusion-needle catheter ablation for ventricular tachycardia, non-invasive cardiac radio-ablation, and sinus node-sparing hybrid ablation as experimental, investigational or unproven. Pulsed field ablation is considered an equally acceptable alternative to standard radiofrequency ablation for medically necessary indications.

Watch I49.8

Get one email when a payer policy names I49.8, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code I49.8?

There are 22 tracked policy changes affecting code I49.8, including updates from Medicare/CMS - Transmittals, UnitedHealthcare, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code I49.8?

Payers that have issued tracked updates for code I49.8 include: Medicare/CMS - Transmittals, UnitedHealthcare, Blue Cross & Blue Shield of Mississippi, Blue Cross Blue Shield of North Dakota, Independence Blue Cross, Excellus BlueCross BlueShield, Aetna.

How do I get notified when code I49.8 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code I49.8. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code I49.8?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

R14022OTN: International Classification of Diseases, 10th Revision (ICD-10) and Other Coding Revisions to National Coverage Determinations (NCDs)- April 2027.

Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (UMR)

Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (Surest)

Preventive Care Services

Preventive Care Services

Autonomic Nervous System Testing

Implantable Cardioverter Defibrillator

Medical Policy Updates for Non-Migrated Members

Ambulatory Electrocardiographic (AECG) Monitoring

Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (Exchange)

Annual ICD-10 and Quarterly CPT/HCPCS Code Updates (Commercial)

MA11.060i, Catheter Ablation of Cardiac Arrhythmias

MA11.011i, Ventricular Assist Devices (VADs)

Preventive Care Services

Cardiac Event Monitors 2.01.03

Genetic Testing for Cardiac Ion Channelopathies 2.02.38

Cardiac Catheter Ablation (CPB 0165, reviewed 2026-08-25)

Tilt Table Testing (CPB 0299, reviewed 2026-05-15)

Apnea Monitors for Infants (CPB 0003, reviewed 2026-03-05)

Leadless Cardiac Pacemaker (CPB 0893, reviewed 2025-12-22)

Quantitative Sensory Testing Methods (CPB 0357, reviewed 2026-05-22)

Cardiac Catheter Ablation (CPB 0165)

What insurance policy changes affect code I49.8?

Which payers have updated policy for code I49.8?

How do I get notified when code I49.8 policy changes?

Why do payers change policies for code I49.8?